Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AARTIDRUGS | NSE
-5.25
-1.41%
Healthcare
Drug Manufacturers-Specialty & Generic
31/03/2024
24/04/2026
366.70
371.05
374.20
363.25
Aarti Drugs Limited through its subsidiaries engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories including anti-inflammatory cardioprotectants antidiarrhoeals antifungals antiarthritis/osteoporosis antibiotics antidiabetics Alzheimer's treatment sedatives vitamins and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole celecoxib ciprofloxacin clopidogrel diclofenac ketoconazole nimesulide and raloxifene. It also offers specialty chemical products such as benzene sulphonamide benzene sulphonic acid benzene sulphonic acid methyl ester benzene sulphonyl chloride cipro Q acid levofloxacin Q acid methyl nicotinate N-methyl methane sulphonamide diphenyl sulphone norofloxacin Q acid ofloxacin Q acid ortho para toluene sulphonamide ortho/para toluene sulphonic acid methyl ester para chloro benzene sulphonamide para chloro benzene sulphonyl chloride para toluene sulphonamide para toluene sulphonic acid methyl ester para toluene sulphonyl chloride and sodium benezene sulfinate as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate bisphenol " C bisphenol "" C(chloride) ethyl nicotinate ethyl para toluene sulphonate and N-methyl imidazole. In addition the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai India."
View LessSmallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
27.3%1 month
41.3%3 months
33.4%6 months
34.0%27.18
-
3.59
0.44
0.23
16.11
2.06
-
3.02B
33.51B
350.22M
0.20
9.49
-30.00
-16.00
13.87
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
35.50
Range1M
60.05
Range3M
103.25
Rel. volume
0.77
Price X volume
40.87M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| RPG Life Sciences Limited | RPGLIFE | Drug Manufacturers-Specialty & Generic | 2033.1 | 33.64B | 1.08% | 50.00 | 0.00% |
| ZOTA | ZOTA | Biotechnology | 1292.2 | 33.50B | 0.59% | n/a | 105.90% |
| Gufic Biosciences Limited | GUFICBIO | Drug Manufacturers-Specialty & Generic | 298.3 | 29.92B | 0.61% | 50.00 | 62.51% |
| Orchid Pharma Limited | ORCHPHARMA | Drug Manufacturers-Specialty & Generic | 566.85 | 28.86B | 0.01% | 59.92 | 11.56% |
| Bliss Gvs Pharma Limited | BLISSGVS | Drug Manufacturers-Specialty & Generic | 262.68 | 27.66B | -2.27% | 17.04 | 10.32% |
| Dishman Carbogen Amcis Limited | DCAL | Biotechnology | 169.01 | 26.50B | -3.17% | n/a | 41.09% |
| Unichem Laboratories Limited | UNICHEMLAB | Drug Manufacturers-Specialty & Generic | 372.35 | 26.31B | -3.39% | n/a | 10.48% |
| Alembic Limited | ALEMBICLTD | Drug Manufacturers-Specialty & Generic | 91.42 | 23.56B | -2.15% | 12.29 | 0.42% |
| Morepen Laboratories Limited | MOREPENLAB | Drug Manufacturers-Specialty & Generic | 41.72 | 23.05B | -2.27% | 37.53 | 3.42% |
| Panacea Biotec Limited | PANACEABIO | Biotechnology | 368.55 | 23.00B | 3.38% | n/a | 2.49% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| "SAI SILKS (KALAMANDIR) LIMITED " | KALAMANDIR | Apparel Retail | 105.44 | 15.54B | -1.25% | 28.83 | 43.67% |
| Signpost India Limited | SIGNPOST | Advertising Agencies | 261.58 | 15.33B | -2.64% | 30.54 | 80.30% |
| V2 Retail Limited | V2RETAIL | Apparel Retail | 203.06 | 7.24B | -2.11% | 120.49 | 191.28% |
| Bhagyanagar India Ltd | BHAGYANGR | Copper | 219.34 | 7.09B | 1.49% | 36.36 | 52.08% |
| Madhav Copper Limited | MCL | Copper | 59 | 1.63B | -1.55% | 82.22 | 32.14% |
| Cubex Tubings Limited | CUBEXTUB | Copper | 89.31 | 1.30B | -1.13% | 35.85 | 21.78% |
| Touchwood Entertainment Limited | TOUCHWOOD | Advertising Agencies | 75.31 | 839.62M | 0.39% | 50.06 | 4.88% |
| Sagardeep Alloys Limited | SAGARDEEP | Copper | 23.58 | 409.35M | -2.16% | 58.62 | 43.14% |
| Heads UP Ventures Limited | HEADSUP | Apparel Retail | 7.29 | 159.72M | 0.00% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 16.11 | 24.85 | Cheaper |
| Ent. to Revenue | 2.06 | 11.40 | Cheaper |
| PE Ratio | 27.18 | 51.36 | Cheaper |
| Price to Book | 3.59 | 6.83 | Cheaper |
| Dividend Yield | 0.20 | 0.52 | Poor |
| Std. Deviation (3M) | 33.40 | 42.17 | Lower Risk |
| Debt to Equity | 0.44 | 0.35 | Expensive |
| Debt to Assets | 0.23 | 0.17 | Expensive |
| Market Cap | 33.51B | 290.82B | Emerging |